Difficulty sleeping is arecognised tobacco withdrawal symptom, but sleep problems, like application site reactions, are commonly reported as adverse reactions to transdermal nicotine therapy. However, no studies have examined potential predictive factors associated with the occurrence of expected adverse experiences during transdermal nicotine therapy. The subject of skin tolerability among patients with a history of eczema, psoriasis or other skin disorders is of particular interest, as are the relationships between plasma concentrations of nicotine, concurrent smoking, sleep problems and nausea.
The cohort study involving 1392 participants was designed to assess the timing, severity and predictive factors of adverse experiences reported during 24-hour transdermal nicotine therapy. Data were collected on patients aged 18 to 70 years old who were smokers and who had expressed a strong desire to stop smoking. The intervention consisted of brief behavioural counselling, a booklet containing smoking cessation advice and instructions for use of the patches, and a 12-week course of decreasing transdermal nicotine doses.
Follow-up was available on 1392 out of 1481 study participants. The majority of adverse experiences were mild. Sleep problems occurred in 669 out of 1392 (48%) participants and most often commenced on the day of smoking cessation. Application site reactions occurred in 478 out of 1392 (34%) participants and most often occurred after 6 days of therapy. No predictor had an adjusted hazard ratio above 2. Statistically significant (p < 0.05) predictors of sleep problems were successfully quitting smoking and female gender. Predictors of application site reactions were psoriasis or eczema, other skin conditions, age <40 years, female gender, place of birth outside Australasia, and trade or university education level.
Substantially increased nicotine intake during therapy compared with baseline smoking occurred in 8% of participants who smoked concurrently, and 4% of participants who did not (p = 0.1). Increased nicotine intake was associated with a modest increase in the overall rate of adverse experiences (89% vs 63%, p = 0.04) and dizziness/lightheadedness (17% vs 3%, p = 0.03), but not with sleep problems or cardiovascular events.
Transdermal nicotine therapy appears to be well tolerated, even if the user smokes concurrently. Sleep disturbance during therapy appeared to be primarily associated with tobacco withdrawal rather than with nicotine excess from treatment with transdermal nicotine. Study participants with pre-existing skin disorders were somewhat more likely to report mild application site reactions than other participants.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Imperial Cancer Research Fund General Practice Research Group. Effectiveness of a nicotine patch in helping people stop smoking: results of a randomised trial in general practice. BMJ 1993; 306: 1304–8
Richmond RL, Harris K, de Almeida Neto A. The transdermal nicotine patch: results of a randomised placebo-controlled trial. Med J Aust 1994; 161: 130–5
Hurt RD, Dale LC, Fredrickson PA, et al. Nicotine patch therapy for smoking cessation combined with physician advice and nurse follow-up: one year outcome and percentage of nicotine replacement. JAMA 1994; 271: 595–600
Gourlay SG, Forbes A, Marriner T, et al. A randomised clinical trial of a second course of transdermal nicotine therapy. BMJ 1995; 311: 363–6
Campbell IA, Prescott RJ, Tjeder-Burton SM. Transdermal nicotine plus support in patients attending hospital with smoking-related diseases: a placebo-controlled study. Respir Med 1996; 90: 47–51
Sachs DP, Säwe U, Leischow SJ. Effectiveness of a 16-hour transdermal nicotine patch in a medical practice setting, without intensive group therapy. Arch Intern Med 1993; 153: 1881–90
Jorenby DE, Smith SS, Fiore MC, et al. Varying nicotine patch dose and type of smoking cessation counseling. JAMA 1995; 274: 1347–52
Transdermal nicotine study group. Transdermal nicotine for smoking cessation. JAMA 1991; 266: 3133–8
Gourlay SG, Forbes A, Marriner T, et al. A prospective study of factors predicting smoking cessation using transdermal nicotine therapy. BMJ 1994; 309: 842–6
Gourlay SG, Benowitz NL, Forbes A, et al. Determinants of plasma concentrations of nicotine and cotinine during smoking and transdermal nicotine treatment. Eur J Clin Pharmacol 1997; 51(5): 407–14
Gourlay SG, McNeil JJ. Antismoking products. Med J Aust 1990; 153: 699–707
Dwyer CM, Forsyth A. Allergic contact dermatitis from methacrylates in a nicotine transdermal patch. Contact Dermatitis 1994; 30: 309–10
Bircher AJ, Howald H, Rufli T. Adverse skin reactions to nicotine in a transdermal therapeutic system. Contact Dermatitis 1991; 25: 230–6
Smith EW, Smith KA, Maibach HI, et al. The local side effects of transdermally absorbed nicotine. Skin Pharmacol 1992; 5: 69–76
Hogan DJ, Maibach HI. Adverse dermatological reactions to transdermal drug delivery systems. J Am Acad Dermatol 1992; 22: 811–4
Greenland S, Satterfield MH, Lanes SF. A meta-analysis to assess the incidence of adverse effects associated with the trans-dermal nicotine patch. Drug Safety 1998; 18: 297–308
Wolter TD, Hauri PJ, Schroeder DR, et al. Effects of 24-hr nicotine replacement on sleep and daytime activity during smoking cessation. Prev Med 1996; 25: 601–10
Davila DG, Hurt RD, Offord KP, et al. Acute effects of trans-dermal nicotine on sleep architecture, snoring, and sleep-disordered breathing in nonsmokers. Am J Respir Crit Care Med 1994; 150: 469–74
Silagy C, Mant D, Fowler G, et al. Metaanalysis on efficacy of nicotine replacement therapies in smoking cessation. Lancet 1994; 343: 139–42
Benowitz NL, Chan K, Denaro CP, et al. Stable isotope method for studying transdermal drug absorption. Clin Pharm Ther 1991; 50: 286–93
Tonnesen P, Norregaard J, Simonsen K, et al. A double-blind trial of a 16-hour transdermal nicotine patch in smoking cessation. N Engl J Med 1991; 325: 311–5
Russell MAH, Stapleton JA, Feyerabend C, et al. Targeting heavy smokers in general practice: randomised controlled trial of transdermal nicotine patches. Br J Med 1993; 306: 1308–12
Foulds J, Stapleton J, Hayward M, et al. Transdermal nicotine patches with low-intensity support to aid smoking cessation in outpatients in a general hospital. Arch Fam Med 1993; 2: 417–23
Kornitzer M, Boutsen M, Dramaix M, et al. Combined use of nicotine patch and gum in smoking cessation: a placebo-controlled clinical trial. Prev Med 1995; 24: 41–7
Benowitz NL, Gourlay SG. The cardiovascular safety of nicotine: implications for nicotine replacement therapy. JACC 1997; 29: 1422–31
Working Group for the Study of Transdermal Nicotine in Patients With Coronary Artery Disease. NRT for patients with coronary artery disease. Arch Intern Med 1994; 154: 989–95
Joseph AM, Norman SM, Ferry LH, et al. The safety of trans-dermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med 1996; 335: 1792–8
About this article
Cite this article
Gourlay, S.G., Forbes, A., Marriner, T. et al. Predictors and Timing of Adverse Experiences During Transdermal Nicotine Therapy. Drug-Safety 20, 545–555 (1999). https://doi.org/10.2165/00002018-199920060-00007
- Adis International Limited
- Smoking Cessation
- Sleep Problem
- Nicotine Replacement Therapy